CARsgen Therapeutics' CAR-T therapy zevor-cel gains inclusion in China's 2025 Innovative Drug Catalogue, highlighting regulatory support and improved patient access for relapsed/refractory multiple myeloma treatment.

CARsgen's BCMA-targeted CAR-T therapy, zevor-cel, gains inclusion in China's 2025 Innovative Drug Catalogue, enhancing access and reimbursement for treating relapsed/refractory multiple myeloma.